Logo Lanfrica
  • Home
  • Atlas
  • Insights
  • Docs
  • Sign in

© 2026 Lanfrica. All rights reserved. All copyrights of the resources shown on the Lanfrica website belong to the original copyright holders, unless explicitly stated otherwise.

Universal Test, Treat, and Keep: Improving ART Retention is Key in Cost-effective HIV Control in Uganda

Domain:

healthcare

Record type:

model
Creator:
N MI ARN M S
Host:avatar
Background: With ambitious new UNAIDS targets to end AIDS by 2030, and new WHO treatment guidelines, there is increased interest in the best way to scale-up ART coverage. We investigate the cost-effectiveness of various ART scale-up options in Uganda. Methods: Individual-based HIV/ART model of Uganda, calibrated using history matching. 22 ART scale-up strategies were simulated from 2016-2030, comprising different combinations of six single interventions (1. increased HIV testing rates, 2. no CD4 threshold for ART initiation, 3. improved ART retention, 4. increased ART restart rates, 5. improved linkage to care, 6. improved pre-ART care). The incremental net monetary benefit (NMB) of each intervention was calculated, for a wide range of different willingness/ability to pay (WTP) per DALY averted (health-service perspective, 3% discount rate). Results: For all WTP thresholds above $210, interventions including removing the CD4 threshold were likely to be most cost-effective. At a WTP of $715 (1 × per-capita-GDP) interventions to improve linkage to and retention/re-enrolment in HIV care were highly likely to be more cost-effective than interventions to increase rates of HIV testing. At higher WTP (>~$1690), the most cost-effective option was 'Universal Test, Treat, and Keep' (UTTK), which combines interventions 1-5 detailed above. Conclusions: Our results support new WHO guidelines to remove the CD4 threshold for ART initiation in Uganda. With additional resources, this could be supplemented with interventions aimed at improving linkage to and/or retention in HIV care. To achieve the greatest reductions in HIV incidence, a UTTK policy should be implemented.

Visit

figshare.com

Tags

No keyword

Licenses

All rights reserved

Similar

Effect of universal test and treat on retention and mortality among people living with HIV-infection in Uganda: An interrupted time series analysisUptake and effect of universal test-and-treat on twelve months retention and initial virologic suppression in routine HIV program in KenyaCommunity-Wide Universal HIV Test and Treat Intervention Reduces Tuberculosis Transmission in Rural Uganda: A Cluster-Randomized TrialUniversal Access to HIV Treatment versus Universal ‘Test and Treat’: Transmission, Drug Resistance & Treatment CostsInvesting in social and behavior change is cost-effective for improving malaria behaviors in TanzaniaEffects, cost, and cost-effectiveness of universal test and treat versus continued scale-up of ART at CD4 count ≤350 cells/µl in South Africa over the period 2012–2050 (Model D).

Effect of universal test and treat on retention and mortality among people living with HIV-infection in Uganda: An interrupted time series analysis

Background Few studies have analysed the effect of HIV universal test and treat (UTT) on retention

Uptake and effect of universal test-and-treat on twelve months retention and initial virologic suppression in routine HIV program in Kenya

Early combination antiretroviral therapy (cART), as recommended in WHO’s universal test-and-treat (U

Community-Wide Universal HIV Test and Treat Intervention Reduces Tuberculosis Transmission in Rural Uganda: A Cluster-Randomized Trial

Abstract Background Human immunodeficiency

Universal Access to HIV Treatment versus Universal ‘Test and Treat’: Transmission, Drug Resistance & Treatment Costs

In South Africa (SA) universal access to treatment for HIV-infected individuals in need has

Investing in social and behavior change is cost-effective for improving malaria behaviors in Tanzania

The Breakthrough RESEARCH business case for investing in social and behavior change (SBC) for malari

Effects, cost, and cost-effectiveness of universal test and treat versus continued scale-up of ART at CD4 count ≤350 cells/µl in South Africa over the period 2012–2050 (Model D).

Costs and effects are discounted at an annual rate of 3%. Life-years concern the total life-years